Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomized controlled trials

Amirhossein Sahebkar, L.E. Simental-Mendía, Gerald Watts, J. Golledge

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

© 2015. Objective: The aim of this systematic review was to perform a meta-analysis of randomized controlled trials (RCTs) examining the efficacy of fibrate therapy in reducing plasma concentration or activity of plasminogen activator inhibitor 1 (PAI-1). Methods: Scopus and MEDLINE databases were searched (up to October 15, 2014) to identify RCTs investigating whether fibrates lower plasma PAI-1 concentration or activity. A random-effects model and the generic inverse variance method were used for quantitative data synthesis. Sensitivity analyses were conducted using the one-study remove approach. Random-effects meta-regression was performed to assess the impact of potential moderators on the estimated effect sizes. Results: A total of 14 RCTs examining the effects of gemfibrozil (6 trials), bezafibrate (4 trials), and fenofibrate (5 trials) were included. Meta-analysis suggested that fibrate therapy did not significantly reduce plasma PAI-1 concentration (weighed mean difference [WMD]:-11.39ng/mL, 95% CI:-26.64, 3.85, p=0.143) or activity (WMD: 2.02U/mL, 95% CI:-0.87, 4.90, p=0.170). These results remained unchanged after subgroup analysis according to duration of treatment (
Original languageEnglish
Pages (from-to)284-296
JournalAtherosclerosis
Volume240
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint Dive into the research topics of 'Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomized controlled trials'. Together they form a unique fingerprint.

Cite this